Organism: Homo sapiens
Gene: 39225_at
Selected probe(set): 225114_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39225_at (225114_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-4.634524
Number of Samples:3 / 6

Experimental	SDF study 4
	MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h.
Control	untreated MDA Mb231 cell sample
	Untreated MDA Mb231 cells harvested after 6h.

Relative Expression (log2-ratio):-3.152275
Number of Samples:3 / 3

Experimental	lactic acid study 1 (hypoxia)
	Breast epithelial cells exposed to 25mM lactic acid of pH6.7 and 2% hypoxia. ATC code:
Control	untreated breast epithelial cell sample
	Breast epithelial cells in control media under normoxia.

Relative Expression (log2-ratio):3.0948095
Number of Samples:6 / 15

Experimental	precursor-B-ALL study 3 (PAX5-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	precursor-B-ALL study 3 (TEL-AML1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):2.9358282
Number of Samples:75 / 441

Experimental	CML study 1
	Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control	B-CLL study 5
	Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

Relative Expression (log2-ratio):-2.715888
Number of Samples:441 / 74

Experimental	B-CLL study 5
	Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-2.715476
Number of Samples:2 / 2

Experimental	zalypsis study 2
	OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control	untreated OPM1 cell sample
	OPM1 multiple myeloma cells untreated.

Relative Expression (log2-ratio):2.6545725
Number of Samples:2 / 4

Experimental	expO breast cancer study 1 (papillary carcinoma, NOS; primary)
	Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control	expO breast cancer study 1 (ductal and lobular carcinoma; primary)
	Primary tumor tissue samples obtained from the breast of patients with ductal and lobular carcinoma.

Relative Expression (log2-ratio):2.623579
Number of Samples:2 / 2

Experimental	bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control	bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

Relative Expression (log2-ratio):2.6006784
Number of Samples:3 / 4

Experimental	expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
	Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control	expO kidney cancer study 1 (granular cell carcinoma; primary)
	Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

Relative Expression (log2-ratio):-2.5828676
Number of Samples:20 / 19

Experimental	atopic dermatitis study 12 (non-lesional; adults)
	Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control	atopic dermatitis study 12 (non-lesional; children)
	Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.